Today: 20 March 2026
Browse Category

NASDAQ:BBIO 5 January 2026 - 16 January 2026

BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next

BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next

BridgeBio Pharma shares rose 0.5% to $76.66 Friday after announcing a $550 million convertible notes sale with a 0.75% interest rate and a $110.58 conversion price. The company expects $538.4 million in net proceeds and plans to use funds to repay 2027 notes and for general purposes. Trading volume reached about 5.9 million shares. The sale is set to close January 21.
16 January 2026

Stock Market Today

  • Nevada Temporarily Bans Prediction Market Firm Kalshi Over Gaming License Dispute
    March 20, 2026, 2:30 PM EDT. Kalshi, a prediction markets platform offering event-based contracts on sports, elections, and entertainment, was temporarily banned in Nevada by a 14-day restraining order from the First Judicial District Court. The ruling prohibits Kalshi from operating its derivatives exchange without a gaming license, marking the first state-level forced cessation for the company. The ban follows earlier Nevada cease-and-desist actions and precedes a likely extension through the legal case, said gaming attorney Daniel Wallach. The dispute comes amid mounting regulatory scrutiny nationally, including criminal charges from Arizona and ongoing battles in multiple states. Kalshi contends its sports contracts are financial swaps, not gambling, a view supported by the federal Commodity Futures Trading Commission, which claims jurisdiction over these markets. This case highlights tensions between state gambling laws and federally regulated prediction markets.
Go toTop